Similar articles

• Discovery of ximelagatran in an historical perspective.

  Gustafsson D. Gustafsson D. Semin Vasc Med. 2005 Aug;5(3):227-34. doi: 10.1055/s-2005-916161. Semin Vasc Med. 2005. PMID: 16123909 Review.
• Orally active direct thrombin inhibitors.

  Weitz J. Weitz J. Semin Vasc Med. 2003 May;3(2):131-8. doi: 10.1055/s-2003-40671. Semin Vasc Med. 2003. PMID: 15199476 Review.
• Novel anticoagulants and the future of anticoagulation.

  Garcia D. Garcia D. Thromb Res. 2009;123 Suppl 4:S50-5. doi: 10.1016/S0049-3848(09)70144-6. Thromb Res. 2009. PMID: 19303505 Review.
• The clinical implications of new oral anticoagulants: will the potential advantages be achieved?

  Phillips KW, Ansell J. Phillips KW, et al. Thromb Haemost. 2010 Jan;103(1):34-9. doi: 10.1160/TH09-06-0361. Epub 2009 Dec 1. Thromb Haemost. 2010. PMID: 20062925 No abstract available.
• Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.

  Kamali F, Wood P, Ward A. Kamali F, et al. Ann Hematol. 2009 Feb;88(2):141-9. doi: 10.1007/s00277-008-0565-x. Epub 2008 Aug 21. Ann Hematol. 2009. PMID: 18716776